We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
EAMS scientific opinion issued to GlaxoSmithKline UK Limited for dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates...
Projects granted during 2015 that have a primary purpose of translational and applied research: projects on human cancer.
Projects granted during 2014 that have a primary purpose of translational and applied research: human cancer.
Overview of the UK's cancer research infrastructure and the advantages of investing in the UK's life science sector to develop new treatments.
Projects granted during 2015 that have a primary purpose of basic research: oncology.
Government bringing together experts in the field to drive forward progress in tackling cancer in children and young people.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of breast cancer.
Chief Medical Officer for England, Professor Chris Whitty's annual reports and lectures on medicine and public health.
Advice for medical professionals to follow when assessing drivers with neurological disorders.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
The CMA acts to help NHS patients access combination therapies used to treat serious medical conditions.
Work out the VAT liability of goods and services supplied by health and care institutions and providers of non residential care to children.
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.